$CNSP
CNS Pharmaceuticals, Inc.

2023 Q3 Form 10-Q Financial Statement

#000168316823005609 Filed on August 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.123M $1.180M
YoY Change -7.25% -12.15%
% of Gross Profit
Research & Development $3.411M $2.846M
YoY Change 54.47% 28.1%
% of Gross Profit
Depreciation & Amortization $3.180K $1.000K
YoY Change 13.57% -68.75%
% of Gross Profit
Operating Expenses $4.534M $4.025M
YoY Change 32.61% 12.93%
Operating Profit -$4.534M -$4.025M
YoY Change 32.61% 12.93%
Interest Expense $1.838K $3.650K
YoY Change 241.64% 126.57%
% of Operating Profit
Other Income/Expense, Net $11.05K $4.152K
YoY Change -2152.97% -357.73%
Pretax Income -$4.523M -$4.021M
YoY Change 32.26% 12.77%
Income Tax
% Of Pretax Income
Net Earnings -$4.523M -$4.021M
YoY Change 32.26% 12.77%
Net Earnings / Revenue
Basic Earnings Per Share -$1.08 -$1.04
Diluted Earnings Per Share -$1.08 -$1.04
COMMON SHARES
Basic Shares Outstanding 4.202M shares 4.143M shares
Diluted Shares Outstanding 4.177M shares 3.877M shares

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $909.6K $4.279M
YoY Change -87.06% -52.23%
Cash & Equivalents $909.5K $4.279M
Short-Term Investments
Other Short-Term Assets $1.152M $1.792M
YoY Change -31.12% -26.52%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $2.062M $6.071M
YoY Change -76.3% -46.73%
LONG-TERM ASSETS
Property, Plant & Equipment $3.470K $3.382K
YoY Change -59.28% -69.17%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $262.7K $377.2K
YoY Change -71.72% -63.69%
Total Long-Term Assets $266.2K $380.6K
YoY Change -71.61% -63.75%
TOTAL ASSETS
Total Short-Term Assets $2.062M $6.071M
Total Long-Term Assets $266.2K $380.6K
Total Assets $2.328M $6.452M
YoY Change -75.84% -48.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.027M $3.571M
YoY Change 300.67% 627.39%
Accrued Expenses $260.1K
YoY Change -5.94%
Deferred Revenue
YoY Change
Short-Term Debt $41.90K $166.4K
YoY Change 6.72% 6.39%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.069M $3.997M
YoY Change 226.99% 332.66%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $4.069M $3.997M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $4.069M $3.997M
YoY Change 226.99% 332.66%
SHAREHOLDERS EQUITY
Retained Earnings -$64.19M -$59.67M
YoY Change 43.44% 44.36%
Common Stock $4.207K $4.141K
YoY Change -89.49% -89.66%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.741M $2.454M
YoY Change
Total Liabilities & Shareholders Equity $2.328M $6.452M
YoY Change -75.84% -48.17%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$4.523M -$4.021M
YoY Change 32.26% 12.77%
Depreciation, Depletion And Amortization $3.180K $1.000K
YoY Change 13.57% -68.75%
Cash From Operating Activities -$3.374M -$3.403M
YoY Change 86.11% 1.2%
INVESTING ACTIVITIES
Capital Expenditures $1.740K $0.00
YoY Change -215.23% -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$1.740K $0.00
YoY Change 15.23% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 9.560K 2.571M
YoY Change -108.16% -2313.55%
NET CHANGE
Cash From Operating Activities -3.374M -3.403M
Cash From Investing Activities -1.740K 0.000
Cash From Financing Activities 9.560K 2.571M
Net Change In Cash -3.366M -831.3K
YoY Change 74.27% -76.12%
FREE CASH FLOW
Cash From Operating Activities -$3.374M -$3.403M
Capital Expenditures $1.740K $0.00
Free Cash Flow -$3.375M -$3.403M
YoY Change 86.36% 1.28%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001729427
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39126
dei Entity Registrant Name
EntityRegistrantName
CNS Pharmaceuticals, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-2318545
dei Entity Address Address Line1
EntityAddressAddressLine1
2100 West Loop South
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 900
dei Entity Address City Or Town
EntityAddressCityOrTown
Houston
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77027
dei City Area Code
CityAreaCode
800
dei Local Phone Number
LocalPhoneNumber
946-9185
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
CNSP
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
4201930 shares
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4279251 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10055407 usd
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1791775 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2509238 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
6071026 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
12564645 usd
CY2023Q2 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
377196 usd
CY2022Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
482806 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3382 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5664 usd
CY2023Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
380578 usd
CY2022Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
488470 usd
CY2023Q2 us-gaap Assets
Assets
6451604 usd
CY2022Q4 us-gaap Assets
Assets
13053115 usd
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3570638 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3681900 usd
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
260137 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
828391 usd
CY2023Q2 us-gaap Notes Payable Current
NotesPayableCurrent
166396 usd
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
409968 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3997171 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4920259 usd
CY2023Q2 us-gaap Liabilities
Liabilities
3997171 usd
CY2022Q4 us-gaap Liabilities
Liabilities
4920259 usd
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4140960 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4140960 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1617325 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1617325 shares
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
4141 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1617 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
62119150 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
58846916 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-59668858 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-50715677 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
2454433 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
8132856 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6451604 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13053115 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1179833 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1343002 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2538585 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2603411 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2845553 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2221339 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6413312 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4110142 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
4025386 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
3564341 usd
us-gaap Operating Expenses
OperatingExpenses
8951897 usd
us-gaap Operating Expenses
OperatingExpenses
6713553 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4025386 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3564341 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-8951897 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-6713553 usd
CY2023Q2 us-gaap Interest Income Operating
InterestIncomeOperating
7802 usd
CY2022Q2 us-gaap Interest Income Operating
InterestIncomeOperating
0 usd
us-gaap Interest Income Operating
InterestIncomeOperating
7802 usd
us-gaap Interest Income Operating
InterestIncomeOperating
0 usd
CY2023Q2 us-gaap Interest Expense
InterestExpense
3650 usd
CY2022Q2 us-gaap Interest Expense
InterestExpense
1611 usd
us-gaap Interest Expense
InterestExpense
9086 usd
us-gaap Interest Expense
InterestExpense
4177 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4152 usd
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1611 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1284 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4177 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-4021234 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-3565952 usd
us-gaap Net Income Loss
NetIncomeLoss
-8953181 usd
us-gaap Net Income Loss
NetIncomeLoss
-6717730 usd
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.04
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.67
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.10
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.11
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.04
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.67
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.10
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.11
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3877317 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1334417 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2893682 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1314241 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3877317 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1334417 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2893682 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1314241 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
8132856 usd
CY2023Q1 CNSP Stock Issued For Exercise Of Warrants
StockIssuedForExerciseOfWarrants
609 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
290313 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4931947 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
3491831 usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1969107 usd
CY2023Q2 CNSP Stock Issued For Exercise Of Warrants
StockIssuedForExerciseOfWarrants
725059 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
289670 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-4021234 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
2454433 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
6163197 usd
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
10625786 usd
CY2022Q1 CNSP Stock Issued For Exercise Of Warrants
StockIssuedForExerciseOfWarrants
2616 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
336685 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3151778 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
13976506 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
286841 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-3565952 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
10697395 usd
us-gaap Net Income Loss
NetIncomeLoss
-8953181 usd
us-gaap Net Income Loss
NetIncomeLoss
-6717730 usd
us-gaap Share Based Compensation
ShareBasedCompensation
579983 usd
us-gaap Share Based Compensation
ShareBasedCompensation
623526 usd
us-gaap Depreciation
Depreciation
2282 usd
us-gaap Depreciation
Depreciation
6581 usd
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-0 usd
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-1467 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-823073 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-259297 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-111262 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-664498 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-568254 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
51624 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8227359 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6439733 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
-0 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2909 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2909 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
243572 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
231397 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
725668 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2616 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1969107 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
10625786 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2451203 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10397005 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-5776156 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
3954363 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10055407 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5004517 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4279251 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8958880 usd
us-gaap Interest Paid Net
InterestPaidNet
9086 usd
us-gaap Interest Paid Net
InterestPaidNet
4813 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
us-gaap Nature Of Operations
NatureOfOperations
<p id="xdx_804_eus-gaap--NatureOfOperations_zMWYbN50ov0i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 1 – <span id="xdx_828_zpFeyHVSp4Bl">Nature of Business</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CNS Pharmaceuticals, Inc. (“we”, “our”, the “Company”) is a clinical pharmaceutical company organized as a Nevada corporation on July 27, 2017 to focus on the development of anti-cancer drug candidates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2023Q2 us-gaap Cash Uninsured Amount
CashUninsuredAmount
4029251 usd
CY2022Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
449874 usd
CY2022Q4 us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.0588 pure
CY2022Q4 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2023-10-31
CY2023Q2 us-gaap Notes Payable Current
NotesPayableCurrent
166396 usd
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
409968 usd
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
29988 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y2M12D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
8133 usd
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
46248 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
725668 usd
CY2021 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
800000 usd
CY2020Q2 us-gaap Payments For Fees
PaymentsForFees
775000 usd
CY2020Q2 us-gaap Development Costs
DevelopmentCosts
1000000.0 usd

Files In Submission

Name View Source Status
0001683168-23-005609-index-headers.html Edgar Link pending
0001683168-23-005609-index.html Edgar Link pending
0001683168-23-005609.txt Edgar Link pending
0001683168-23-005609-xbrl.zip Edgar Link pending
cnsp-20230630.xsd Edgar Link pending
cns_ex3101.htm Edgar Link pending
cns_ex3102.htm Edgar Link pending
cns_ex3201.htm Edgar Link pending
cns_ex3202.htm Edgar Link pending
cns_i10q-063023.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
cnsp-20230630_pre.xml Edgar Link unprocessable
cnsp-20230630_cal.xml Edgar Link unprocessable
cnsp-20230630_def.xml Edgar Link unprocessable
cnsp-20230630_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
cns_i10q-063023_htm.xml Edgar Link completed